Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “neutral” rating and set a $5.00 target price on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

Minerva Neurosciences stock opened at $2.11 on Tuesday. The stock has a market cap of $14.75 million, a price-to-earnings ratio of -4.80 and a beta of 0.11. The firm has a 50-day moving average of $2.21 and a two-hundred day moving average of $2.57. Minerva Neurosciences has a 1 year low of $2.03 and a 1 year high of $13.49.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.